Tanya Siddiqi, M.D.
Hematologist
4.9 (287 RATINGS)
Clinical Expertise
CAR T Cell Therapy
Chronic lymphocytic leukemia
Hematopoietic Cell Transplantation
Lymphoma
Appointments
Medical Director, Division of Lymphoma, City of Hope Orange County
Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center
Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly chronic lymphocytic leukemia (CLL) and B cell non-Hodgkin lymphoma (B-NHL).
In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy) and other novel agents primarily in diseases like CLL and B-NHL.
Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by fellowships in hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.
Dr. Siddiqi is a member of the Toni Stephenson Lymphoma Center, immunotherapy disease team and the Gehr Family Center for Leukemia Research.
2000, M.B.B.S., Aga Khan University Medical College, Karachi, Pakistan
2009-2010, Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2006-2009, Hmatology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
2003-2006, Internal Medicine, University of Connecticut Health Center, Farmington, Connecticut
2019-present, Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center, City of Hope, Duarte, California
2018-present - Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2010-2018, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2013-present, Supervising Physician, Outpatient Anticoagulation Clinic, City of Hope, Duarte, California
2009-2010, Instructor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2016, Best Lymphoma Abstract Award, Lymphoma and Myeloma, New York, New York, October 13-15, 2016
2016, Pasadena Magazine Top Doctor, August 2016
2012, Phase 1 Program Correlative Science Award, City of Hope
2009, Tim Nesvig Lymphoma Foundation Grant
2008, American Association for Cancer Research Molecular Biology in Clinical Oncology Workshop Award
American Society of Blood and Marrow Transplantation
American Society of Clinical Oncology
American Society of Hematology
Member, National Comprehensive Cancer Network VTD Panel
Member, National Comprehensive Cancer Networ, CLL\NHL Panel
- Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA. Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood Adv. 2022 Dec 14:bloodadvances.2022009164. doi: 10.1182/bloodadvances.2022009164. Epub ahead of print. PMID: 36516082.
- Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei MG, Popplewell LL, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022 Nov 10;140(19):2024-2036. doi: 10.1182/blood.2022016747. PMID: 35914220
- Al Malki MM, Palmer J, Tsai N-C, Mokhtari S, Hui S, Tsai W, Aldoss I, Ali H, Aribi A, Cao T, Mei M, Sandhu KS, Siddiqi T, Forman SJ, Nakamura R, Marcucci G, Stein A, Wong JYC, Rosenthal J. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Adv. 2022 Jul 26;6(14):4098-4106. doi: 10.1182/bloodadvances.2022007264. PMID: 35838754
- Kambhampati S, Mei MG, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. PD-1 blockade after avelumab in relapsed/refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 2022 Jun 6;S2152-2650(22)00185-9. doi: 10.1016/j.clml.2022.06.004. Online ahead of print. PMID: 35778267
- Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022 Jun;20(6):622-634. doi: 10.6004/jnccn.2022.0031. PMID: 35714675
- Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, Siddiqi T, Popplewell L, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam N. Cost effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B cell lymphoma. Blood. 2022 Jun 14:blood.2022016624. doi: 10.1182/blood.2022016624; online ahead of print. PMID: 35700381
- Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther. 2022 May 21:S2666-6367(22)01319-7. doi: 10.1016/j.jtct.2022.05.026. Online ahead of print. PMID: 35609867
- Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O’Brien S. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma. 2022 Jul;63(7):1580-1588. doi: 10.1080/10428194.2022.2038372. Epub 2022 Feb 28. PMID: 35227147
- Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488. PMID: 35196370
- Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Fuhrman RR, Treon SP. Venetoclax in previously treated Waldenstrom macroglobulinemia. J Clin Oncol 2022; 40: 63-71. PMID: 34793256
- Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895. PMID: 34699592
- Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Fertrin KY, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Ibrahim I, Kraut E, Leavitt AD, Lee A, Lee JT, Lim M, Mann J, Martin K, McMahon B, Moriarty J, Morton C, Ortel TL, Paschal R, Schaefer J, Shattil S, Siddiqi T, Sudheendra D, Williams E, Hollinger L, Nguyen MQ. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Oct 15;19(10):1181-1201. doi: 10.6004/jnccn.2021.0047. PMID: 34666313
- Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 Oct 7: JCO2100807. doi: 10.1200/JCO.21.00807. Online ahead of print. PMID: 34618601
- Siddiqi T, Wang X, Blanchard MS, Wagner JR, Popplewell LL, Budde LE, Stiller TL, Clark MC, Lim L, Vyas V, Brown CE, Forman SJ. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021 Oct 26;5(20):4059-4063. doi: 10.1182/bloodadvances.2020004106. PMID: 34492703
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. PMID: 34478487
- Woyach J, Tedeschi A, Munir T, Siddiqi T, Hillmen P, Byrd JC, Ghia P, Mulligan SP, Dai S, Amaya-Chanaga CI, Dean JP, O'Brien SM, Barr PM. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871. Online ahead of print. PMID: 34384312
- Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisnewski P, Patel K, Shadman M, Park B, Danilov AV. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 2021 Jun 24:clincanres.3993.2020. doi: 10.1158/1078-0432.CCR-20-3993. Online ahead of print. PMID: 34168050
- Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan W-C, Meffre E, Martin T, Muschen M. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Mol Cell. 2021 May 20;81(10):2094-2111.e9. doi: 10.1016/j.molcel.2021.03.043. Epub 2021 Apr 19. PMID: 33878293
- Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, Snyder S, McGarvey N, Gitlin M, Pelletier C, Jun MP. Cytokine release syndrome and neurological event costs in liscabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021 Mar 23;5(6):1695-1705. doi: 10.1182/bloodadvances.2020003531. PMID: 33720336
- Danilov AV, Spurgeon SE, Siddiqi T, Quinson A-M, Maier D, Smith D, Brown JR. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 8. PMID: 33683501
Chapters:
- Siddiqi T. Chronic lymphocytic leukemia: Biology and Treatment. Siddiqi T. (2021) Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. In: Pullarkat V., Marcucci G. (eds) Biology and Treatment of Leukemia and Bone Marrow Neoplasms. Cancer Treatment and Research, vol 181. Springer, Cham. https://doi.org/10.1007/978-3-030-78311-2_8
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
4.9
Recommend this provider office
Reviews
02/08/23
This was my first appointment with Dr Siddiqi and it was outstanding. She was communicative and knowledgeable, friendly and professional. Absolutely great - Verified patient
02/02/23
The Dr was super knowledgeable kind caring and took her time to answer my questions and explain everything for me to understand her. Thank you so much Dr - Verified patient
02/02/23
Great service and very friendly and love the clean environment. - Verified patient
01/31/23
Dr Siddiqi is very good. She is knowledgeable and caring. - Verified patient
01/25/23
Everything perfect - Verified patient